New tech aims to sharpen lung cancer radiation targeting

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologic proof of malignancy suitable for thoracic radiation therapy * Patient is planning to undergo radiation therapy for primary or recurrent malignancies of the lung or metastatic malignancies to the lung. * Age ≥ 18 years old * Karnofsky Performance Status ≥ 60% * At least part of the tumor must be visible as observed in a diagnostic or planning CT. * Able to have bronchoscopic placement of Calypso transponders as confirmed on a recent (within the past 8 weeks) CT scan. Exclusion Criteria: * Patients with clinically significant active infections. * Bronchiectasis in the region of the intended implantation. * History of hypersensitivity to nickel. * Other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study. * Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines * Unable to tolerate anesthesia or sedation * Enrolled in any other clinical studies the investigator believes to be in conflict with this investigation. * Female patients who are pregnant or nursing Exclusion criteria for Calypso transponders: * Implants in the chest region that contain metal or conductive materials (e.g., metal implants, rods, or plates) which Calypso Medical considers will interfere with the Calypso System's electromagnetic localization. * Active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown. * Patients whose lung tumors are being monitored by MR imaging as part of standard clinical care. Implantation of transponders will degrade MR images. * Posterior lesions that would be \>19 cm distance from Calypso detector plate.